Using MIPs for medicine

– Imprinting a difference

Welcome to MipSalus

MipSalus is dedicated to developing new, non-systemic pharmaceutical drugs for treatment of metabolic orphan diseases

New proprietary drug

MipSalus is developing a new proprietary drug – the first in a new class of medicines – for the treatment of all variants of HPA (Hyperphenylalaninemia)

The disease

Phenylketonuria (PKU) is a rare metabolic disorder. People with PKU cannot metabolize phenylalanine (Phe), an amino acid found in all kinds of dietary protein.

Home sensor

MipSalus is committed to developing a home sensor allowing PKU patients to conveniently monitor the concentration of phenylalanine (Phe) in their blood.


NICOLAS O. KROGHCEO and member of the Board
KLAUS GREGORIUSCSO and member of the Board
JENS PETER TOFTChairman of the Board


MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment for the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to prevent uptake of surplus dietary phenylalanine (Phe) in the body.

The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.

Furthermore, building on the PKU drug development project and using company’s Phe-binding MIPs, MipSalus has obtained in-vitro proof of concept for a home sensor that will enable PKU patients to monitor their disease and swiftly adjust food and medication accordingly.